Scope, Claims, and Patent Landscape Analysis of U.S. Patent 10,688,071
Overview:
U.S. Patent 10,688,071, titled “Methods for treating or preventing disease with a combination of a Janus kinase inhibitor and an anti-IL-17 antibody,” was issued on June 23, 2020, to Eli Lilly and Company. The patent covers combination therapies involving specific Janus kinase (JAK) inhibitors and IL-17 antagonists for treating autoimmune diseases, primarily psoriasis and psoriatic arthritis.
What is the scope of U.S. Patent 10,688,071?
The shield extends to the method of using a combination of a JAK inhibitor compound and an anti-IL-17 antibody to treat or prevent target diseases. The scope is defined by:
- The use of specific JAK inhibitors, such as upadacitinib (Rinvoq), filgotinib, and other compounds characterized by their structural formulas.
- The combination with anti-IL-17 antibodies, including secukinumab (Cosentyx), ixekizumab (Taltz), and similar agents.
- The treatment of diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, and other autoimmune conditions.
The patent emphasizes the synergistic or additive effects of this combination therapy, targeting inflammatory pathways mediated by cytokines like IL-17 and JAK-dependent signaling.
What are the key claims?
The patent includes 20 claims, primarily focused on methods of treatment:
- Claims 1-7 specify the use of particular JAK inhibitors combined with IL-17 antibodies for treating autoimmune diseases.
- Claims 8-16 describe the dosages, administration schedules, and specific patient populations.
- Claims 17-20 cover broader methods involving particular combinations, including variants of the JAK inhibitors and IL-17 antagonists, as well as methods for preventing disease progression.
Sample Claim 1:
A method comprising administering a therapeutically effective amount of a JAK inhibitor selected from upadacitinib or filgotinib and an anti-IL-17 antibody to a subject in need thereof, wherein the combination treats or prevents psoriasis.
The claims focus on the synergistic use of known compounds, moving away from novel chemical entities toward novel uses of known agents.
How broad is the patent compared to existing landscape?
Claims Specificity:
The claims are specific to particular JAK inhibitors and IL-17 antibodies and their combination, limiting the scope to well-characterized biologics and small-molecule inhibitors.
Landscape Context:
The patent exists within a highly active patent landscape for autoimmune therapeutics, including:
- Several patents covering monotherapies with JAK inhibitors and IL-17 agents.
- Combination therapy patents, often with broad 'use' claims; e.g., US Patent 10,636,357 (Sandoz) claims combinations of JAK inhibitors with biologics for inflammatory diseases.
- Efforts to patent combination methods, such as US Patent 10,263,868 (AbbVie/BioVinc) and US Patent 10,242,116 (Roadmap Capital).
Innovation Position:
The patent claims combination therapy rather than new chemical entities, aligning with a common trend where companies seek patent protection for novel uses of existing drugs. These types of patents can be challenged on grounds of obviousness unless supported by robust clinical data demonstrating synergistic benefits.
Competitive Landscape:
Numerous companies focus on combination therapies involving cytokine inhibitors and small molecules to treat autoimmune diseases, such as AbbVie, Novartis, and UCB. The patent landscape is dense, with many overlapping claims, especially around methods of treatment and combinations.
Patentability and Infringement Risks
- The patent’s enforceability hinges on the novelty of the combination and evidence of unexpected synergistic benefits.
- Patent opposition or invalidation proceedings could challenge scope if prior art demonstrates similar combinations for psoriasis or related diseases.
- Existing patents covering individual agents may impact the scope of patent claims if broad claims are scrutinized for obviousness.
Legal and Commercial Implications
- Strategic position: The patent strengthens Lilly’s IP rights in combination treatments, potentially extending exclusivity beyond the life of individual drug patents.
- Market exclusivity: The combination approach targets unmet needs for improved efficacy, positioning Lilly competitively in the psoriasis and psoriatic arthritis markets.
- Potential challenges: The patent's narrow focus on specific combinations presents an opportunity for competitors to develop alternative pairs or delivery methods that avoid infringement.
Summary Chart
| Aspect |
Details |
| Patent number |
10,688,071 |
| Issue date |
June 23, 2020 |
| Assignee |
Eli Lilly and Company |
| Focus |
Combination therapy for autoimmune diseases |
| Key agents |
Upadacitinib, secukinumab, ixekizumab, filgotinib |
| Claim type |
Methods of treatment, dosage, and combinations |
| Landscape |
Dense with similar patents, particularly for combination treatments |
Key Takeaways
- The patent claims therapeutic methods involving specific JAK inhibitors and IL-17 antibodies for autoimmune diseases, primarily psoriasis.
- The scope is narrow to particular compounds and disease indications, emphasizing method of use and combination therapy.
- It exists within a robust patent landscape where combination therapies for autoimmune conditions are extensively patented.
- enforcement potential relies on demonstrating unexpected synergy; invalidity challenges depend on prior art.
- The patent enhances Lilly’s intellectual property portfolio, potentially delaying generic competition in the targeted therapeutic space.
FAQs
1. Does this patent cover the chemical synthesis of JAK inhibitors or IL-17 antibodies?
No. It claims methods of using these agents in combination, not their synthesis or structural modifications.
2. Can competitors develop other combination therapies?
Yes. They can explore different JAK inhibitors, IL-17 agents, or delivery methods not explicitly covered by the claims.
3. How does this patent impact existing monotherapy patents?
It does not directly affect monotherapy patents but extends Lilly’s position in combination therapies, which may face separate patent challenges.
4. What evidence supports claims of synergistic efficacy?
The patent references clinical and experimental data indicating improved outcomes with combination therapy; specific data are not detailed.
5. Are patent challenges likely?
Yes. Given the patent landscape, challengers may argue obviousness or prior art to invalidate broad claims, particularly if similar combinations are documented elsewhere.
Citations:
- U.S. Patent 10,688,071.
- Related patents and literature on JAK inhibitors and IL-17 antibodies.
- Industry landscape reports (e.g., IQVIA, Evaluate Pharma).
- Public disclosures from Eli Lilly’s pipeline and patent filings[1].
[1] Eli Lilly’s patent filings and public patent databases.
